首页 > 最新文献

Skinmed最新文献

英文 中文
Perleche. 佩莱切。
Q4 Medicine Pub Date : 2022-10-31 eCollection Date: 2022-01-01
Mark Bernhardt
{"title":"Perleche.","authors":"Mark Bernhardt","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40446318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Herpes Zoster after mRNA COVID-19 Vaccination: A Case Series. mRNA - COVID-19疫苗接种后带状疱疹:一个病例系列
Q4 Medicine Pub Date : 2022-08-31 eCollection Date: 2022-01-01
Alexandra Monastirli, Efstathia Pasmatzi, George Badavanis, Gianna Panagiotopoulou, Assimina Apostolidou, Dionysios Tsambaos

We present seven immunocompetent patients devoid of any comorbidities and risk factors, who developed for the first time in their life varicella-zoster virus (VZV) reactivation shortly after 1st (four patients) and 2nd dose (three patients) of mRNA COVID-19 vaccines.All four patients who exhibited herpes zoster after the 1st dose of vaccine received the 2nd dose without any adverse reactions or complications. Oral treatment prescribed to all patients with valacyclovir (Valtrex 1 mg tds/day) for 5-7 days led to a complete resolution of symptoms, and rashes disappeared within 9-14 days. Presently, All patients have completed a 3-4½-month follow-up without any evidence of complications and/or recurrence of herpes zoster. (SKINmed. 2022;20:284-288).

我们报告了7例无任何合并症和危险因素的免疫功能正常的患者,他们在第一次(4例)和第二次(3例)mRNA COVID-19疫苗接种后不久首次出现水痘带状疱疹病毒(VZV)再激活。所有4例在接种第一剂疫苗后出现带状疱疹的患者均接受了第二剂疫苗,没有出现任何不良反应或并发症。所有患者口服valacyclovir (Valtrex 1mg tds/day)治疗5-7天,症状完全缓解,皮疹在9-14天内消失。目前,所有患者都完成了3-4个半月的随访,没有任何并发症和/或带状疱疹复发的证据。(SKINmed。20:284 2022; 288)。
{"title":"Herpes Zoster after mRNA COVID-19 Vaccination: A Case Series.","authors":"Alexandra Monastirli,&nbsp;Efstathia Pasmatzi,&nbsp;George Badavanis,&nbsp;Gianna Panagiotopoulou,&nbsp;Assimina Apostolidou,&nbsp;Dionysios Tsambaos","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We present seven immunocompetent patients devoid of any comorbidities and risk factors, who developed for the first time in their life varicella-zoster virus (VZV) reactivation shortly after 1st (four patients) and 2nd dose (three patients) of mRNA COVID-19 vaccines.All four patients who exhibited herpes zoster after the 1st dose of vaccine received the 2nd dose without any adverse reactions or complications. Oral treatment prescribed to all patients with valacyclovir (Valtrex 1 mg tds/day) for 5-7 days led to a complete resolution of symptoms, and rashes disappeared within 9-14 days. Presently, All patients have completed a 3-4½-month follow-up without any evidence of complications and/or recurrence of herpes zoster. (<i>SKINmed</i>. 2022;20:284-288).</p>","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40716888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oranges, Lemon, Lind, and the 275th Anniversary of the Salisbury Experiment: A Few Words. 橙子、柠檬、林德和索尔兹伯里实验275周年:几句话。
Q4 Medicine Pub Date : 2022-08-31 eCollection Date: 2022-01-01
Amiya Kumar Mukhopadhyay, Lawerence Charles Parish
{"title":"Oranges, Lemon, Lind, and the 275<sup>th</sup> Anniversary of the Salisbury Experiment: A Few Words.","authors":"Amiya Kumar Mukhopadhyay,&nbsp;Lawerence Charles Parish","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40633601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roxburgh's Common Skin Diseases. Roxburgh的常见皮肤病。
Q4 Medicine Pub Date : 2022-08-31 eCollection Date: 2022-01-01
Michael Waugh
{"title":"Roxburgh's Common Skin Diseases.","authors":"Michael Waugh","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40716900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adolescents Seeking Cosmetic Treatment as a Consequence of Social Media Pressure: Treatment for the Problem of Aging or the Problem of the Ages? 青少年因社交媒体压力而寻求美容治疗:治疗衰老问题还是年龄问题?
Q4 Medicine Pub Date : 2022-08-31 eCollection Date: 2022-01-01
Nicole Gherlone, Kerry Heitmiller, Nazanin Saedi
{"title":"Adolescents Seeking Cosmetic Treatment as a Consequence of Social Media Pressure: Treatment for the Problem of Aging or the Problem of the Ages?","authors":"Nicole Gherlone,&nbsp;Kerry Heitmiller,&nbsp;Nazanin Saedi","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40633602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VTAMA® (Tapinarof) Cream* for Plaque Psoriasis. VTAMA®(Tapinarof)乳霜*治疗银屑病。
Q4 Medicine Pub Date : 2022-08-31 eCollection Date: 2022-01-01
Aditya K Gupta, Shruthi Polla Ravi, Kimberly Vincent, William Abramovits

VTAMA® (Tapinarof) 1% cream is a newly approved topical agent for treating plaque psoriasis. The active ingredient, tapinarof, binds to and activates aryl hydrocarbon receptors that positively regulate immune response and skin homeostasis. Tapinarof has presented promising results in two identical phase 3 randomized, double-blind, vehicle-controlled trials, where the primary efficacy end points were observed in 35.4% and 40.2% of patients in the tapinarof group compared to 6.0% and 6.3% of patients in the vehicle group. Tapinarof was applied once daily to affected psoriasis lesions for 12 weeks. Adverse events associated with tapinarof application were folliculitis, contact dermatitis, and headache. (SKINmed. 2022;20:298-300).

VTAMA®(Tapinarof) 1%乳膏是一种新批准的治疗斑块型银屑病的局部用药。活性成分tapinarof结合并激活芳烃受体,积极调节免疫反应和皮肤稳态。Tapinarof在两项相同的3期随机、双盲、载药对照试验中显示出令人满意的结果,Tapinarof组的主要疗效终点分别为35.4%和40.2%,而载药组的主要疗效终点分别为6.0%和6.3%。Tapinarof每天一次应用于受影响的牛皮癣病变,持续12周。与tapinarof应用相关的不良事件有毛囊炎、接触性皮炎和头痛。(SKINmed。20:298 2022; 300)。
{"title":"VTAMA<sup>®</sup> (Tapinarof) Cream* for Plaque Psoriasis.","authors":"Aditya K Gupta,&nbsp;Shruthi Polla Ravi,&nbsp;Kimberly Vincent,&nbsp;William Abramovits","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>VTAMA<sup>®</sup> (Tapinarof) 1% cream is a newly approved topical agent for treating plaque psoriasis. The active ingredient, tapinarof, binds to and activates aryl hydrocarbon receptors that positively regulate immune response and skin homeostasis. Tapinarof has presented promising results in two identical phase 3 randomized, double-blind, vehicle-controlled trials, where the primary efficacy end points were observed in 35.4% and 40.2% of patients in the tapinarof group compared to 6.0% and 6.3% of patients in the vehicle group. Tapinarof was applied once daily to affected psoriasis lesions for 12 weeks. Adverse events associated with tapinarof application were folliculitis, contact dermatitis, and headache. (<i>SKINmed</i>. 2022;20:298-300).</p>","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40716892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rising Rates of COVID-19 Lead to Increased Searches for "Maskne". COVID-19发病率上升导致“口罩”搜索量增加。
Q4 Medicine Pub Date : 2022-08-31 eCollection Date: 2022-01-01
Pushkar Aggarwal, Suraj Muddasani, Alan B Fleischer
{"title":"Rising Rates of COVID-19 Lead to Increased Searches for \"Maskne\".","authors":"Pushkar Aggarwal,&nbsp;Suraj Muddasani,&nbsp;Alan B Fleischer","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40716897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unna Nevus and Seborrheic Keratosis: Dermatoscopic Imitations. 乌纳痣和脂溢性角化病:皮肤镜下的模仿。
Q4 Medicine Pub Date : 2022-08-31 eCollection Date: 2022-01-01
Khatuna Kudava
{"title":"Unna Nevus and Seborrheic Keratosis: Dermatoscopic Imitations.","authors":"Khatuna Kudava","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40716898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methotrexate Toxicity: A Case Series from a Tertiary Care Center in Northern India. 甲氨蝶呤毒性:来自印度北部三级保健中心的病例系列。
Q4 Medicine Pub Date : 2022-08-31 eCollection Date: 2022-01-01
Nancy Bhardwaj, Payal Chauhan, Rashmi Jindal, Samarjit Roy

Methotrexate is widely prescribed by various specialists, including internists, dermatologists, rheumatologists, orthopedics, and oncologists. The clinical features of acute methotrexate toxicity vary and are influenced by the acute cumulative dose, duration of methotrexate, associated risk factors, comorbidities, and drug interactions. We present a series of six patients with acute methotrexate toxicity. The characteristics of their clinical presentation, diagnoses, and risk factors are highlighted. All patients were given intravenous leucovorin and other supportive treatments. This series highlights the importance of thorough counseling for patients regarding the course of disease for which methotrexate is prescribed and the dosing, schedule, and adverse effects that are associated with methotrexate. Physician awareness, diagnosis, and treatment are crucial for mitigating the complications of methotrexate toxicity. (SKINmed. 2022;20:274-281).

甲氨蝶呤被各种专家广泛使用,包括内科医生、皮肤科医生、风湿病学家、骨科医生和肿瘤学家。急性甲氨蝶呤毒性的临床特征各不相同,并受急性累积剂量、甲氨蝶呤持续时间、相关危险因素、合并症和药物相互作用的影响。我们报告了6例急性甲氨蝶呤中毒的患者。强调了他们的临床表现、诊断和危险因素的特点。所有患者均给予静脉注射亚叶酸素及其他支持性治疗。本系列强调了对甲氨蝶呤处方的病程以及与甲氨蝶呤相关的剂量、时间表和不良反应进行彻底咨询的重要性。医师的认识、诊断和治疗对于减轻甲氨蝶呤毒性并发症至关重要。(SKINmed。20:274 2022; 281)。
{"title":"Methotrexate Toxicity: A Case Series from a Tertiary Care Center in Northern India.","authors":"Nancy Bhardwaj,&nbsp;Payal Chauhan,&nbsp;Rashmi Jindal,&nbsp;Samarjit Roy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Methotrexate is widely prescribed by various specialists, including internists, dermatologists, rheumatologists, orthopedics, and oncologists. The clinical features of acute methotrexate toxicity vary and are influenced by the acute cumulative dose, duration of methotrexate, associated risk factors, comorbidities, and drug interactions. We present a series of six patients with acute methotrexate toxicity. The characteristics of their clinical presentation, diagnoses, and risk factors are highlighted. All patients were given intravenous leucovorin and other supportive treatments. This series highlights the importance of thorough counseling for patients regarding the course of disease for which methotrexate is prescribed and the dosing, schedule, and adverse effects that are associated with methotrexate. Physician awareness, diagnosis, and treatment are crucial for mitigating the complications of methotrexate toxicity. (<i>SKINmed</i>. 2022;20:274-281).</p>","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40716887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pachydermoperiostosis with Hearing Loss. 厚皮积膜病伴听力损失。
Q4 Medicine Pub Date : 2022-08-31 eCollection Date: 2022-01-01
Dilbag Singh, Ritu Rawat, Vishal Thakur

A 21-year-old unmarried man, born of a non-consanguineous marriage, presented to the dermatology department with progressive thickening of the facial skin and eyelids, plus increased folds over his forehead for the last 5 months. He also complained of progressive enlargement of his hands and feet, with intermittent joint pains in his wrists, elbows, and ankles, along with occasional abdominal pain. He had a hearing loss and increased sweating. (SKINmed. 2022;20:311-313).

21岁未婚男性,非近亲婚生子,面部皮肤和眼睑进行性增厚,前额褶皱增多,近5个月就诊于皮肤科。患者还主诉手脚渐进式肿大,伴有腕、肘、踝关节间歇性疼痛,偶有腹痛。他听力下降,出汗增多。(SKINmed。20:311 2022; 313)。
{"title":"Pachydermoperiostosis with Hearing Loss.","authors":"Dilbag Singh,&nbsp;Ritu Rawat,&nbsp;Vishal Thakur","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 21-year-old unmarried man, born of a non-consanguineous marriage, presented to the dermatology department with progressive thickening of the facial skin and eyelids, plus increased folds over his forehead for the last 5 months. He also complained of progressive enlargement of his hands and feet, with intermittent joint pains in his wrists, elbows, and ankles, along with occasional abdominal pain. He had a hearing loss and increased sweating. (<i>SKINmed</i>. 2022;20:311-313).</p>","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40716896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Skinmed
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1